{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:21:00Z","timestamp":1769919660259,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical Research Council Clinician Scientist"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.08.086","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T02:32:39Z","timestamp":1479954759000},"page":"489-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Controlled human infection with RSV: The opportunities of experimental challenge"],"prefix":"10.1016","volume":"35","author":[{"given":"Maximillian S.","family":"Habibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.08.086_b0005","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.08.086_b0010","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0015","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0020","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.08.086_b0025","doi-asserted-by":"crossref","first-page":"L148","DOI":"10.1152\/ajplung.00065.2011","article-title":"Animal models of human respiratory syncytial virus disease","volume":"301","author":"Bem","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0030","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1214247110","article-title":"Neonatal antibody responses are attenuated by interferon-\u03b3 produced by NK and T cells during RSV infection","author":"Tregoning","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2016.08.086_b0035","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.4049\/jimmunol.179.12.8410","article-title":"CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections","volume":"179","author":"Heidema","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0040","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1086\/657158","article-title":"Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults","volume":"202","author":"Eun-Hyung Lee","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.086_b0045","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1164\/rccm.201002-0221OC","article-title":"Viral load drives disease in humans experimentally infected with respiratory syncytial virus","volume":"182","author":"DeVincenzo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.086_b0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.coviro.2013.05.005","article-title":"Protective and dysregulated T cell immunity in RSV infection","volume":"3","author":"Openshaw","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0060","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu075","article-title":"Protecting the family to protect the child: vaccination strategy guided by RSV transmission dynamics","author":"Graham","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.086_b0065","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1378\/chest.13-1567","article-title":"AIrway inflammation and illness severity in response to experimental rhinovirus infection in asthma","volume":"145","author":"Zhu","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.vaccine.2016.08.086_b0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1465-9921-7-116","article-title":"An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study","volume":"7","author":"Mallia","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.vaccine.2016.08.086_b0075","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1084\/jem.20151025","article-title":"Interferon-driven alterations of the host\u2019s amino acid metabolism in the pathogenesis of typhoid fever","volume":"213","author":"Blohmke","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/jme.2003.004440","article-title":"Challenge studies of human volunteers: ethical issues","volume":"30","author":"Hope","year":"2004","journal-title":"J Med Ethics"},{"key":"10.1016\/j.vaccine.2016.08.086_b0085","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1038\/ncomms10224","article-title":"RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection","volume":"6","author":"Jozwik","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2016.08.086_b0090","first-page":"657","article-title":"Respiratory syncytial virus. III. Production of illness and clinical observations in adult volunteers. JAMA","volume":"176","author":"Kravetz","year":"1961","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2016.08.086_b0095","first-page":"123","article-title":"Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness","volume":"107","author":"Mills","year":"1971","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2016.08.086_b0100","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jmv.1890250405","article-title":"Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers","volume":"25","author":"McKay","year":"1988","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0264-410X(90)90051-M","article-title":"Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines","volume":"8","author":"Watt","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.086_b0110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1128\/IAI.33.3.779-783.1981","article-title":"Infectivity of respiratory syncytial virus by various routes of inoculation","volume":"33","author":"Hall","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.08.086_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0166-3542(90)90061-B","article-title":"The efficacy of intranasal interferon\u03b1-2a in respiratory syncytial virus infection in volunteers","volume":"14","author":"Higgins","year":"1990","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2016.08.086_b0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.086_b0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2004.04.005","article-title":"Experimental infection of humans with A2 respiratory syncytial virus","volume":"63","author":"Lee","year":"2004","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2016.08.086_b0130","series-title":"Human immune responses to respiratory syncytial virus","author":"Cherrie","year":"1992"},{"key":"10.1016\/j.vaccine.2016.08.086_b0135","doi-asserted-by":"crossref","first-page":"e113100","DOI":"10.1371\/journal.pone.0113100","article-title":"Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged Memphis-37 Challenge Virus","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.086_b0140","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Influenza: Developing Drugs for Treatment and\/or Prophylaxis. 2011. <http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm091219.pdf> [accessed 31.07.16]."},{"key":"10.1016\/j.vaccine.2016.08.086_b0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2009.07.006","article-title":"Gene expression signatures diagnose influenza and other symptomatic respiratory viral infection in humans","volume":"6","author":"Zaas","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2016.08.086_b0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1164\/rccm.201002-0221OC","article-title":"Viral load drives disease in humans experimentally infected with respiratory syncytial virus","volume":"182","author":"DeVincenzo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0155","doi-asserted-by":"crossref","first-page":"e32807","DOI":"10.1371\/journal.pone.0032807","article-title":"Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication","volume":"7","author":"Eshaghi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.086_b0160","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1128\/JVI.01045-15","article-title":"Functional analysis of the 60-nucleotide duplication in the respiratory syncytial virus buenos aires strain attachment glycoprotein","volume":"89","author":"Hotard","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0170","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","article-title":"Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)","volume":"77","author":"DeVincenzo","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2016.08.086_b0180","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14760584.2014.878653","article-title":"Current concepts and progress in RSV vaccine development","volume":"13","author":"Guvenel","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.08.086_b0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0190","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/cit048","article-title":"Complex correlates of protection after vaccination","volume":"56","author":"Plotkin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.086_b0195","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.086_b0200","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1086\/314726","article-title":"A simple and reproducible method for collecting nasal secretions in frail elderly adults, for measurement of virus-specific IgA","volume":"179","author":"Walsh","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.086_b0205","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/jmv.20724","article-title":"Serum antibody decay in adults following natural respiratory syncytial virus infection","volume":"78","author":"Falsey","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.201412-2256OC","article-title":"Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus","volume":"191","author":"Habibi","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0215","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","article-title":"Virus-specific T cells as correlate of (cross-)protective immunity against influenza","volume":"33","author":"Altenburg","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.086_b0220","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.168.3.1163","article-title":"Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus","volume":"168","author":"Cannon","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0225","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm.3883","article-title":"The emerging role of resident memory T cells in protective immunity and inflammatory disease","volume":"21","author":"Park","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0230","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2568","article-title":"Sensing and alarm function of resident memory CD8+ T cells","volume":"14","author":"Schenkel","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1189\/jlb.0313180","article-title":"Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection","volume":"95","author":"Wu","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2016.08.086_b0240","doi-asserted-by":"crossref","first-page":"e71072","DOI":"10.1371\/journal.pone.0071072","article-title":"A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles","volume":"8","author":"Rigter","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.086_b0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus\u2013 and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.08.086_b0250","first-page":"466","article-title":"Immunity to RSV in early-life","volume":"5","author":"Lambert","year":"2014","journal-title":"Immunother Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T13:27:32Z","timestamp":1601213252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16307939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16307939"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled human infection with RSV: The opportunities of experimental challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}